1. Home
  2. DWTX
  3. DWTX News

Latest DOGWOOD THERAPEUTICS INC (DWTX) News on July 1, 2025

Sidoti Events, LLC's Virtual June Small-Cap Conference
DWTX

ACCESS Newswire

21 days ago

Sidoti Events, LLC's Virtual June Small-Cap Conference

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
DWTX

GlobeNewswire

a month ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway…
DWTX

Zacks Small Cap Research

2 months ago

DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway…

Dogwood Therapeutics Announces First Quarter 2025 Financial Results
DWTX

GlobeNewswire

2 months ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

DWTX

Newsfile

2 months ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
DWTX

GlobeNewswire

3 months ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

DWTX: Interim Data for Phase 2b Trial in 4Q25…
DWTX

Zacks Small Cap Research

3 months ago

DWTX: Interim Data for Phase 2b Trial in 4Q25…

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
DWTX

GlobeNewswire

3 months ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
DWTX

GlobeNewswire

3 months ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

DWTX

MT Newswires

3 months ago

Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
DWTX

GlobeNewswire

3 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…
DWTX

Zacks Small Cap Research

3 months ago

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

Biotech Alert: Searches spiking for these stocks today
DWTX

TipRanks

4 months ago

Biotech Alert: Searches spiking for these stocks today

DWTX

MT Newswires

4 months ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

DWTX

MT Newswires

4 months ago

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
DWTX

GlobeNewswire

4 months ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
DWTX

GlobeNewswire

4 months ago

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
DWTX

GlobeNewswire

5 months ago

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
DWTX

GlobeNewswire

7 months ago

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

DWTX

MT Newswires

8 months ago

Top Premarket Decliners

DWTX: Phase 2 Long COVID Results Expected Soon
DWTX

Zacks Small Cap Research

8 months ago

DWTX: Phase 2 Long COVID Results Expected Soon

DWTX

Thomson Reuters StreetEvents

8 months ago

Q3 2024 Dogwood Therapeutics Inc Earnings Call

DWTX

GuruFocus.com

8 months ago

Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
DWTX

GlobeNewswire

8 months ago

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
DWTX

GlobeNewswire

8 months ago

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
DWTX

GlobeNewswire

8 months ago

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…
DWTX

Zacks Small Cap Research

9 months ago

DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…

Share on Social Networks: